LCT: The cell implant company

Living Cell Technologies Limited (LCT) is a global pioneer in the field of cell encapsulation and implantation for human therapeutics.

LCT is the first company globally to enter clinical trials using therapeutic porcine cell implants. DIABECELL® is designed to help normalise the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycaemia. Tiny DIABECELL microspheres containing live islet cells are implanted into a patient's abdomen using a simple laparoscopic procedure. Once implanted, DIABECELL works by self-regulating and efficiently secreting insulin and glucagon in response to the patient's changing glucose levels. DIABECELL islets are protected from the body's immune response by LCT's breakthrough proprietary encapsulation technology, so DIABECELL patients do not require any immunosuppression.

DIABECELL is currently in late-stage clinical trials, having completed a successful Phase I/IIa clinical trial in Russia and
following the positive results from the interim analysis of the Phase IIa safety and efficacy trial. Safety and preliminary efficacy data generated to date show promise that DIABECELL will change the paradigm for treating diabetes when it becomes the world's first approved porcine cell implant.

On 1 November 2011 LCT and Otsuka Pharmaceutical Factory, Inc. created a new company Diatranz Otsuka Limited (DOL) with cash of $A25,000,000 to accelerate the development and commercialisation of DIABECELL.

Using breakthrough proprietary micro-encapsulation technology, IMMUPEL™, which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL®, a choroid plexus cell product which is currently in
Phase I clinical trials in New Zealand for Parkinson's disease. NTCELL has also shown a powerful ability to regenerate tissue and restore function in animal models of Parkinson’s disease, stroke, Huntington's disease, hearing loss and other non-neurological conditions, such as wound healing.
Fact Sheet Register for email updates >